Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (7): 698-702.doi: 10.35541/cjd.20201116

• Reviews • Previous Articles     Next Articles

Cell therapy for hereditary epidermolysis bullosa

Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen   

  1. Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China
  • Received:2020-11-20 Revised:2021-05-31 Online:2023-07-15 Published:2023-07-04
  • Contact: Zhu Ningwen
  • Supported by:
    Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16040400); Shanghai Municipal Science and Technology Commission Project (19441909900)

Abstract: 【Abstract】 Hereditary epidermolysis bullosa (EB) is a rare mutilating and lethal inherited single-gene skin disease, and places a heavy burden on society and families. Cell therapy has become a very promising method for the treatment of EB due to its excellent and stable clinical efficacy. This review summarizes progress in laboratory research and clinical application of stem cell- and somatic cell-based therapies in EB in recent years.

Key words: Epidermolysis bullosa, Tissue therapy, Stem cells, Tissue-engineered skin, Single-gene genodermatosis